| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000029113 |
| Receipt No. | R000033293 |
| Scientific Title | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis |
| Date of disclosure of the study information | 2017/09/20 |
| Last modified on | 2019/03/17 (Ver. 4) |
| Basic information | ||
| Public title | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | |
| Acronym | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | |
| Scientific Title | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | |
| Scientific Title:Acronym | Clinical study on the effect of fermented buckwheat sprouts in patients with interstitial cystitis | |
| Region |
|
|
| Condition | ||
| Condition | Patients with interstitial cystitis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To study beneficial effect of fermented buckwheat sprouts on patients with interstitial cystitis |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Primary outcomes are clinical questionnaire test (subjective symptom for OABSS, IPSS, bother OABSS,et) and maximal urine before and after repeated oral intake (12 weeks) of fermented buckwheat sprouts |
| Key secondary outcomes | Key secondary outcomes are the following examinations:
1)height, body weight 2)Questionnaire for subjective symptoms for overactive bladder, prostatic hyperplasia, lower urinary tract symptoms and interstitial cystitis, and urination 3)physical examination 4)hematology test 5)quantitative measurements of various clinical biomarkers in the blood and urine. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | NO |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of test food including fermented buckwheat sprouts (12 weeks, 4 tablets / once a day) | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients with interstitial cystitis who exert either pollakiuria, acceleration of urinary desire or urinary urgency in addition to bladder pain
2) Patients who have received confirmed diagnosis of interstitial cystitis by the cystoscopy or hydrostatic dilator in the past. 3) Patients who are not satisfied by the current treatment |
|||
| Key exclusion criteria | 1) Patients with a previous history of urinary tract and genital infection within the past 3 months (excluding asymptomatic pyuria).
2) Patients within 3 months after hydrostatic dilator. 3) Patients with an interstitial cystitis symptom score of less than 9 ( a perfect score of 20) and satisfying the current treatment at more than 50 scores of VAS 4) Patients who have taken in fermented buckwheat sprouts within the past 3 months 5) Patients whose major cause of current symptoms (having bladder pain and frequent urination, urinary acceleration or urinary urgency) may be considered as other diseases (overactive bladder, neurogenic bladder, prostatic hyperplasia etc.) 6) The subjects who have allergy symptoms by buckwheat (test ingredients) 7) The subjects who are judged to be inappropriate by the responsible doctor. |
|||
| Target sample size | 20 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | University of Shizuoka | ||||||
| Division name | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences | ||||||
| Zip code | 422-8526 | ||||||
| Address | 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan | ||||||
| TEL | 054-264-5625 | ||||||
| yamada@u-shizuoka-ken.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | University of Shizuoka | ||||||
| Division name | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences | ||||||
| Zip code | 422-8526 | ||||||
| Address | 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan | ||||||
| TEL | 054-264-5625 | ||||||
| Homepage URL | |||||||
| yamada@u-shizuoka-ken.ac.jp | |||||||
| Sponsor | |
| Institute | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Fujikogei Co. Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Kageyama Hospital (Shizuoka city)
Nakamura Hospital (Beppu city) |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Center for Pharma-Food Research, Graduate School of Pharmaceutical Sciences, University of Shizuoka |
| Address | 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan |
| Tel | 054-264-5625 |
| yamada@u-shizuoka-ken.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 静岡県立大学 薬食生命科学総合学府 薬学研究院 薬食研究推進センター |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033293 |